[go: up one dir, main page]

MA33783B1 - Procédé de préparation de méthyl -{4,6-diamino-2-[1-(2-fluorobenzyl)- 1h-pyrazolo[3,4-b]pyridino-3-yl] pyrimidino-5-yl} méthylcarbamate et d'épuration de ce composé pour son utilisation en tant qu'agent pharmaceutique - Google Patents

Procédé de préparation de méthyl -{4,6-diamino-2-[1-(2-fluorobenzyl)- 1h-pyrazolo[3,4-b]pyridino-3-yl] pyrimidino-5-yl} méthylcarbamate et d'épuration de ce composé pour son utilisation en tant qu'agent pharmaceutique

Info

Publication number
MA33783B1
MA33783B1 MA34924A MA34924A MA33783B1 MA 33783 B1 MA33783 B1 MA 33783B1 MA 34924 A MA34924 A MA 34924A MA 34924 A MA34924 A MA 34924A MA 33783 B1 MA33783 B1 MA 33783B1
Authority
MA
Morocco
Prior art keywords
preparation
pyrimidino
pyridino
methylcarbamate
fluorobenzyl
Prior art date
Application number
MA34924A
Other languages
Arabic (ar)
English (en)
Inventor
Franz-Josef Mais
Joachim Rehse
Winfried Joentgen
Konrad Siegel
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43536603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33783(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA33783B1 publication Critical patent/MA33783B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C325/00—Thioaldehydes; Thioketones; Thioquinones; Oxides thereof
    • C07C325/02—Thioketones; Oxides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé de préparation de méthyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]
MA34924A 2009-11-27 2012-05-25 Procédé de préparation de méthyl -{4,6-diamino-2-[1-(2-fluorobenzyl)- 1h-pyrazolo[3,4-b]pyridino-3-yl] pyrimidino-5-yl} méthylcarbamate et d'épuration de ce composé pour son utilisation en tant qu'agent pharmaceutique MA33783B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09177371 2009-11-27
PCT/EP2010/067949 WO2011064171A2 (fr) 2009-11-27 2010-11-22 Procédé de préparation de méthyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}méthylcarbamate et d'épuration de ce composé pour son utilisation en tant qu'agent pharmaceutique

Publications (1)

Publication Number Publication Date
MA33783B1 true MA33783B1 (fr) 2012-11-01

Family

ID=43536603

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34924A MA33783B1 (fr) 2009-11-27 2012-05-25 Procédé de préparation de méthyl -{4,6-diamino-2-[1-(2-fluorobenzyl)- 1h-pyrazolo[3,4-b]pyridino-3-yl] pyrimidino-5-yl} méthylcarbamate et d'épuration de ce composé pour son utilisation en tant qu'agent pharmaceutique

Country Status (43)

Country Link
US (5) US8492544B2 (fr)
EP (5) EP3415515B1 (fr)
JP (4) JP5859451B2 (fr)
KR (2) KR101861981B1 (fr)
CN (2) CN104059064B (fr)
AR (1) AR079134A1 (fr)
AU (3) AU2010323227B2 (fr)
BR (3) BR122019002289B1 (fr)
CA (2) CA2781799C (fr)
CL (1) CL2012001329A1 (fr)
CO (1) CO6551708A2 (fr)
CR (1) CR20120280A (fr)
CU (1) CU24084B1 (fr)
CY (1) CY1115861T1 (fr)
DK (4) DK2733142T3 (fr)
DO (2) DOP2012000144A (fr)
EA (3) EA036422B1 (fr)
EC (2) ECSP12011921A (fr)
ES (4) ES2553035T3 (fr)
GT (1) GT201200158A (fr)
HR (4) HRP20141073T1 (fr)
HU (2) HUE026778T2 (fr)
IL (4) IL219683A (fr)
JO (3) JO3107B1 (fr)
LT (2) LT2733142T (fr)
MA (1) MA33783B1 (fr)
MX (1) MX2012005938A (fr)
MY (2) MY173711A (fr)
NZ (3) NZ715101A (fr)
PE (2) PE20121742A1 (fr)
PH (1) PH12012501023A1 (fr)
PL (4) PL2604608T3 (fr)
PT (4) PT2604608E (fr)
RS (4) RS54433B1 (fr)
SI (4) SI2504334T1 (fr)
SM (1) SMT201400164B (fr)
TN (1) TN2012000257A1 (fr)
TR (1) TR201816146T4 (fr)
TW (1) TWI496781B (fr)
UA (1) UA110779C2 (fr)
UY (1) UY33048A (fr)
WO (1) WO2011064171A2 (fr)
ZA (1) ZA201204610B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553035T3 (es) 2009-11-27 2015-12-03 Adverio Pharma Gmbh Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1H-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}-metilcarbamato de metilo y su purificación para el uso como principio activo farmacéutico
ME02477B (fr) 2009-11-27 2017-02-20 Genzyme Corp Genz 112638 pour le traitement de la maladie de Gaucher ou de Fabry en polythérapie
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
EA031602B1 (ru) 2011-11-25 2019-01-31 Адверио Фарма Гмбх Способы получения альдегидов
HK1217488A1 (zh) * 2013-02-21 2017-01-13 Adverio Pharma Gmbh {4,6-二氨基-2-[1-(2-氟苄基)-1h-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式
CN104327107A (zh) * 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
JP6664385B2 (ja) 2014-09-19 2020-03-13 バイエル ファーマ アクチエンゲゼルシャフト Ｂｕｂ１阻害薬としてのベンジル置換インダゾール類
WO2016113415A1 (fr) 2015-01-16 2016-07-21 Sandoz Ag Procédé de préparation de riociguat essentiellement exempt d'impuretés génotoxiques
CN105367568B (zh) * 2015-11-18 2019-08-20 浙江京新药业股份有限公司 一种制备利奥西呱的方法
CN105294686B (zh) * 2015-11-30 2017-03-22 郑州大明药物科技有限公司 一种利奥西呱的制备方法
EA201891416A1 (ru) 2015-12-14 2018-12-28 Айронвуд Фармасьютикалз, Инк. ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА
WO2017103760A1 (fr) * 2015-12-15 2017-06-22 Alembic Pharmaceuticals Limited Nouveau polymorphe de riociguat et son procédé de préparation
CN108069960A (zh) * 2016-11-15 2018-05-25 江苏豪森药业集团有限公司 利奥西呱中间体的制备方法
WO2018096550A1 (fr) * 2016-11-28 2018-05-31 Msn Laboratories Private Limited, R&D Center Procédé de préparation de méthyle 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl(méthyl)carbamate et ses polymorphes
US20190381039A1 (en) 2016-12-13 2019-12-19 Cyclerion Therapeutics, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS
WO2018130226A1 (fr) * 2017-01-16 2018-07-19 苏州科睿思制药有限公司 Nouvelle forme cristalline de riociguat, procédé de préparation et utilisation correspondants
US12220414B2 (en) 2018-07-11 2025-02-11 Tisento Therapeutics Inc. Use of sGC stimulators for the treatment of mitochondrial disorders
TWI830835B (zh) 2018-12-17 2024-02-01 德商亞德維瑞醫藥有限公司 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物
JP7780442B2 (ja) * 2020-02-03 2025-12-04 アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング メチル｛４，６－ジアミノ－２－［５－フルオロ－１－（２－フルオロベンジル）－１Ｈ－ピラゾロ［３，４－ｂ］ピリジン－３－イル］ピリミジン－５－イル｝カルバメートのナノ製剤
CN111689961A (zh) * 2020-06-01 2020-09-22 江苏华阳制药有限公司 一种利奧西呱的新晶型及其制备方法
EP3925953A1 (fr) * 2020-06-16 2021-12-22 Adverio Pharma GmbH Procédé de préparation de méthyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
CN112316968B (zh) * 2020-11-13 2022-03-01 中国石油大学(北京) 一种粗对苯二甲酸加氢精制催化剂及其制备方法和应用
CN112316932B (zh) * 2020-11-13 2022-03-01 中国石油大学(北京) 一种粗对苯二甲酸加氢精制催化剂及其制备方法和应用
CN117229282A (zh) * 2023-09-11 2023-12-15 安徽美诺华药物化学有限公司 一种利奥西呱的合成工艺

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950350A (en) * 1974-12-27 1976-04-13 Pfizer Inc. Penam-dimethylsulfoxide complex
US4970210A (en) * 1987-07-17 1990-11-13 Abbott Laboratories Triazinone lipoxygenase compounds
EP0409689B1 (fr) * 1989-07-18 1995-03-22 Elf Atochem S.A. Procédé pour la purification de 1,1-bis(4-chlorophényl)-2,2,2-trichloroéthanol
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
ES2325045T3 (es) 1996-10-14 2009-08-24 Bayer Healthcare Ag Nuevos derivados de pirazol heterociclilmetil sustituidos y su uso en el tratamiento de enfermedades cardiovasculares.
IL135462A0 (en) 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
WO2002042299A1 (fr) 2000-11-22 2002-05-30 Bayer Aktiengesellschaft Nouveaux derives de pyrazolopyridine substitues par lactame
DE10057754A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
DE10057751A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10122894A1 (de) * 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
DE10132416A1 (de) 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
US6738631B1 (en) 2002-05-06 2004-05-18 Nokia, Inc. Vision-guided model-based point-and-click interface for a wireless handheld device
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP4299573B2 (ja) * 2003-04-25 2009-07-22 東洋シヤッター株式会社 エレベータの扉装置
DE10222550A1 (de) 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
DE10351903A1 (de) * 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
KR200342343Y1 (ko) 2003-11-17 2004-02-18 김강철 탄성체 유희용구
WO2005095384A1 (fr) * 2004-04-01 2005-10-13 Astellas Pharma Inc. Dérivés de pyrazine et utilisation pharmaceutique de ceux-ci comme antagonistes de l'adénosine
TWI345568B (en) * 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102009004245A1 (de) * 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
UY33040A (es) 2009-11-27 2011-06-30 Bayer Schering Pahrma Akitengesellschaft Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
UY33041A (es) * 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
ES2553035T3 (es) * 2009-11-27 2015-12-03 Adverio Pharma Gmbh Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1H-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}-metilcarbamato de metilo y su purificación para el uso como principio activo farmacéutico
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
JP6114189B2 (ja) 2010-07-09 2017-04-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 縮合ピリミジンおよびトリアジンならびに心血管障害の処置および／または予防のためのその使用
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
CA2834901A1 (fr) 2011-05-06 2012-11-15 Bayer Intellectual Property Gmbh Imidazopyridazines substituees et imidazopyridazines, et leur utilisation
US20140228366A1 (en) 2011-07-06 2014-08-14 Bayer Intellectual Property Gmbh Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
CA2866213A1 (fr) 2012-03-06 2013-09-12 Bayer Intellectual Property Gmbh Azabicyles substitues et leur utilisation
EA027689B1 (ru) 2013-03-01 2017-08-31 Байер Фарма Акциенгезельшафт Трифторметилзамещенные аннелированные пиримидины и их применение

Also Published As

Publication number Publication date
KR101766931B1 (ko) 2017-08-09
EP2604608A2 (fr) 2013-06-19
CA2781799A1 (fr) 2011-06-03
EA022813B1 (ru) 2016-03-31
JP5859451B2 (ja) 2016-02-10
JP2013512212A (ja) 2013-04-11
JP2017081971A (ja) 2017-05-18
US20180282329A1 (en) 2018-10-04
EP3415515B1 (fr) 2019-12-25
EP2733142B1 (fr) 2018-08-01
HRP20151243T1 (hr) 2015-12-18
RS53585B1 (sr) 2015-02-27
US10570130B2 (en) 2020-02-25
US20110130410A1 (en) 2011-06-02
ZA201204610B (en) 2014-09-25
DK2504334T3 (en) 2014-12-08
AU2017203023A1 (en) 2017-05-25
UY33048A (es) 2011-06-30
HRP20200397T1 (hr) 2020-06-12
JP6371871B2 (ja) 2018-08-08
KR20120123258A (ko) 2012-11-08
US8853398B2 (en) 2014-10-07
WO2011064171A3 (fr) 2011-08-11
ES2553035T3 (es) 2015-12-03
IL251601A0 (en) 2017-06-29
PL3415515T3 (pl) 2020-06-01
DK2604608T3 (en) 2015-12-07
IL240878B (en) 2018-08-30
NZ715101A (en) 2017-07-28
BR122019002291B1 (pt) 2021-04-27
PL2604608T3 (pl) 2016-02-29
BR112012012617B8 (pt) 2021-05-25
CU24084B1 (es) 2015-03-30
PT2504334E (pt) 2014-12-03
PT2733142T (pt) 2018-11-15
MX2012005938A (es) 2012-09-12
AU2010323227B2 (en) 2015-11-19
EA031632B1 (ru) 2019-01-31
KR20170093992A (ko) 2017-08-16
EP2504334B1 (fr) 2014-10-01
SMT201400164B (it) 2015-01-15
CR20120280A (es) 2013-04-22
CL2012001329A1 (es) 2013-07-05
AU2017203023B2 (en) 2018-11-08
SI2733142T1 (sl) 2018-10-30
EP2604608A3 (fr) 2013-08-07
EA201270636A1 (ru) 2013-01-30
ES2524826T3 (es) 2014-12-12
EP2604608B1 (fr) 2015-10-07
AU2015243005B2 (en) 2017-06-01
CN102791707A (zh) 2012-11-21
US20190284186A1 (en) 2019-09-19
HK1178899A1 (en) 2013-09-19
PT2604608E (pt) 2015-11-26
US20130310563A1 (en) 2013-11-21
HK1202292A1 (en) 2015-09-25
JP6133931B2 (ja) 2017-05-24
EP2504334A2 (fr) 2012-10-03
HRP20181785T1 (hr) 2018-12-28
TN2012000257A1 (en) 2013-12-12
ES2693746T3 (es) 2018-12-13
IL251603A0 (en) 2017-06-29
CN104059064A (zh) 2014-09-24
MY173711A (en) 2020-02-17
CA2936852C (fr) 2019-10-29
ECSP12011921A (es) 2012-07-31
HUE040328T2 (hu) 2019-03-28
CN104059064B (zh) 2019-06-04
CN102791707B (zh) 2014-10-29
NZ625983A (en) 2016-02-26
TW201200514A (en) 2012-01-01
PE20180203A1 (es) 2018-01-31
IL251603B (en) 2019-05-30
EP2733142A3 (fr) 2014-10-15
PL2504334T3 (pl) 2015-02-27
RS54433B1 (sr) 2016-04-28
PH12012501023A1 (en) 2014-12-19
HUE026778T2 (en) 2016-08-29
BR112012012617A2 (pt) 2015-09-08
IL240878A0 (en) 2015-10-29
LT2733142T (lt) 2018-10-10
CY1115861T1 (el) 2017-01-25
NZ600199A (en) 2014-06-27
LT3415515T (lt) 2020-03-10
EA201590948A1 (ru) 2016-01-29
EP3699180A1 (fr) 2020-08-26
SI3415515T1 (sl) 2020-03-31
WO2011064171A2 (fr) 2011-06-03
IL251601B (en) 2019-05-30
DK3415515T3 (da) 2020-03-16
EP2733142A2 (fr) 2014-05-21
DOP2012000144A (es) 2012-11-15
CA2781799C (fr) 2017-05-02
IL219683A0 (en) 2012-07-31
SI2504334T1 (sl) 2014-11-28
JP2018150383A (ja) 2018-09-27
CO6551708A2 (es) 2012-10-31
JO3650B1 (ar) 2020-08-27
DOP2020000062A (es) 2020-09-30
RS57790B1 (sr) 2018-12-31
EA036422B1 (ru) 2020-11-09
AU2010323227A1 (en) 2012-06-14
CA2936852A1 (fr) 2011-06-03
TWI496781B (zh) 2015-08-21
PL2733142T3 (pl) 2019-03-29
DK2733142T3 (en) 2018-11-19
ES2775902T3 (es) 2020-07-28
US8492544B2 (en) 2013-07-23
US10030014B2 (en) 2018-07-24
US20140288303A1 (en) 2014-09-25
CU20120082A7 (es) 2012-10-15
BR112012012617B1 (pt) 2021-04-27
EP3415515A1 (fr) 2018-12-19
RS59908B1 (sr) 2020-03-31
UA110779C2 (uk) 2016-02-25
JO3107B1 (ar) 2017-09-20
AR079134A1 (es) 2011-12-28
MY180184A (en) 2020-11-24
JP6514398B2 (ja) 2019-05-15
TR201816146T4 (tr) 2018-11-21
US10351562B2 (en) 2019-07-16
ECSP18018453A (es) 2018-04-30
PE20121742A1 (es) 2012-12-13
PT3415515T (pt) 2020-03-10
SI2604608T1 (sl) 2015-12-31
KR101861981B1 (ko) 2018-05-28
BR122019002291B8 (pt) 2021-05-25
JP2015205887A (ja) 2015-11-19
EA201891964A1 (ru) 2019-01-31
AU2015243005A1 (en) 2015-11-05
HRP20141073T1 (hr) 2015-01-02
IL219683A (en) 2015-09-24
BR122019002289B1 (pt) 2021-09-28
JO3651B1 (ar) 2020-08-27
GT201200158A (es) 2014-04-03

Similar Documents

Publication Publication Date Title
MA33783B1 (fr) Procédé de préparation de méthyl -{4,6-diamino-2-[1-(2-fluorobenzyl)- 1h-pyrazolo[3,4-b]pyridino-3-yl] pyrimidino-5-yl} méthylcarbamate et d'épuration de ce composé pour son utilisation en tant qu'agent pharmaceutique
EP2780307A4 (fr) Procédé de préparation d'hydrofluorooléfines
MA33764B1 (fr) Procédé de fabrication du {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate de méthyle et de purification de celui-ci en vue de son utilisation comme principe actif pharmaceutique
EP2797975A4 (fr) Procédé de préparation d'élastomères de polyuréthane microcellulaires
EP2683757A4 (fr) Procédé de préparation de copolymères de dioxyde de carbone/époxyde contenant des liaisons éther
PH12014500200A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
EP2621857A4 (fr) Procédé de préparation de granulés d'aérogel de silice
EP2718304A4 (fr) Procédé de préparation d'un copolymère éthylène- -oléfine-diène
EP2666471A4 (fr) Composition pharmaceutique pour la traitement de la rate et de l'estomac, ainsi que procédé de préparation de cette composition
EP2621284A4 (fr) Procédé de préparation d'un concentré aqueux de glyphosate
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
EP2508504A4 (fr) Procédé de préparation de monoesters d'acides cycloalcanedicarboxyliques
EP2770996A4 (fr) Procédé de préparation d'agonistes bêta 3 et d'intermédiaires associés
EP2907434A4 (fr) Procédé de traitement d'urgence d'interruption de robot de nettoyage de vitre
EP2605772A4 (fr) Procédé de préparation de composés d'éther d'aminocyclohexyle
EP2521712A4 (fr) Procédé pour la préparation de chlorure de perfluoroalkylsulfényle
EP2716640A4 (fr) Composé d'hexahydrodibenzo[a,g]quinolizine, son procédé de préparation, composition pharmaceutique et son utilisation
CU20120081A7 (es) Nuevas formas polimorfas de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
EP2516369A4 (fr) Procédé pour la préparation de 2,6-diisopropylphénol extra pur
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
EP2471795A4 (fr) Procédé pour la préparation de prasugrel
EP2468710A4 (fr) Procédé de préparation de monohydrate d hexafluoroacétone
EP2756883A4 (fr) Procédé de préparation d'un 2,3,3,3-tétrafluoropropène
EP2508509A4 (fr) Procédé de préparation de composés acides (z)-cyanoalcénylcyclopropanecarboxyliques
EP2885302A4 (fr) Procédé de préparation d'inhibiteurs de dipeptidylpeptidase